Editas Medicine (EDIT) Misses Q1 EPS by 13c

Editas Medicine (NASDAQ: EDIT) reported Q1 EPS of ($0.76), $0.13 worse than the analyst estimate of ($0.63). Revenue for the quarter came in at $1.14 million versus the consensus estimate of $10.99 million.

For earnings history and earnings-related data on Editas Medicine (EDIT) click here.

You May Also Be Interested In

• BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
• L3Harris CEO steps down amid conduct review, shares drop
• BofA Securities Reiterates Buy Rating on Micron Technology (MU); Sees $230+ in EPS by FY30